Pathogenesis of myeloma bone disease

被引:279
作者
Roodman, G. D. [1 ]
机构
[1] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Sch Med, Pittsburgh, PA 15240 USA
关键词
multiple myeloma; osteoclast; osteoblast; bone disease; KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR-NECROSIS-FACTOR; MULTIPLE-MYELOMA; RECEPTOR ACTIVATOR; IN-VIVO; INHIBITS OSTEOCLASTOGENESIS; OSTEOBLAST DIFFERENTIATION; MARROW MICROENVIRONMENT; PROTEASOME INHIBITOR;
D O I
10.1038/leu.2008.336
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. 1 The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.
引用
收藏
页码:435 / 441
页数:7
相关论文
共 75 条
  • [1] Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
    Abe, M
    Hiura, K
    Wilde, J
    Shioyasono, A
    Moriyama, K
    Hashimoto, T
    Kido, S
    Oshima, T
    Shibata, H
    Ozaki, S
    Inoue, D
    Matsumoto, T
    [J]. BLOOD, 2004, 104 (08) : 2484 - 2491
  • [2] Development of an in vivo model of human multiple myeloma bone disease
    Alsina, M
    Boyce, B
    Devlin, RD
    Anderson, JL
    Craig, F
    Mundy, GR
    Roodman, GD
    [J]. BLOOD, 1996, 87 (04) : 1495 - 1501
  • [3] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
    Anderson, G
    Gries, M
    Kurihara, N
    Honjo, T
    Anderson, J
    Donnenberg, V
    Donnenberg, A
    Ghobrial, I
    Mapara, MY
    Stirling, D
    Roodman, D
    Lentzsch, S
    [J]. BLOOD, 2006, 107 (08) : 3098 - 3105
  • [4] New insights in myeloma-induced osteolysis
    Barillé-Nion, S
    Bataille, R
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1463 - 1467
  • [5] Bone disease in myeloma
    Berenson J.R.
    [J]. Current Treatment Options in Oncology, 2001, 2 (3) : 271 - 283
  • [6] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
    Berenson, JR
    Lichtenstein, A
    Porter, L
    Dimopoulos, MA
    Bordoni, R
    George, S
    Lipton, A
    Keller, A
    Ballester, O
    Kovacs, MJ
    Blacklock, HA
    Bell, R
    Simeone, J
    Reitsma, DJ
    Heffernan, M
    Seaman, J
    Knight, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) : 488 - 493
  • [7] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
    Berenson, JR
    Lichtenstein, A
    Porter, L
    Dimopoulos, MA
    Bordoni, R
    George, S
    Lipton, A
    Keller, A
    Ballester, O
    Kovacs, M
    Blacklock, H
    Bell, R
    Simeone, JF
    Reitsma, DJ
    Heffernan, M
    Seaman, J
    Knight, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 593 - 602
  • [8] A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    Body, JJ
    Facon, T
    Coleman, RE
    Lipton, A
    Geurs, F
    Fan, M
    Holloway, D
    Peterson, MC
    Bekker, P
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1221 - 1228
  • [9] Osteoclast differentiation and activation
    Boyle, WJ
    Simonet, WS
    Lacey, DL
    [J]. NATURE, 2003, 423 (6937) : 337 - 342
  • [10] Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Mitsiades, C.
    Chauhan, D.
    Okawa, Y.
    Munshi, N. C.
    Richardson, P. G.
    Anderson, K. C.
    [J]. LEUKEMIA, 2008, 22 (10) : 1925 - 1932